Results 131 to 140 of about 38,749 (246)

Integrated Proteomic and Metabolomic Profiling for Developing Novel Plasma‐Based Diagnostic Models of Sarcopenia

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 1, February 2026.
ABSTRACT Background Sarcopenia is a progressive, age‐related condition characterized by a decline in skeletal muscle mass, strength and performance. Diagnosis remains challenging because current consensus criteria are difficult to scale and existing biomarkers lack accuracy.
Dongqin Xu, Haoran Jin, Jinlin Yang, Zhiliang Zuo, Rui Ou, Fengjuan Hu, Lu Pu, Yuxing Dong, Meng Wu, Birong Dong, Hao Jiang   +10 more
wiley   +1 more source

Cystatin C and Sudden Cardiac Death Risk in the Elderly

, 2010
Rajat Deo, Nona Sotoodehnia, Ronit Katz, Mark J. Sarnak, Linda F. Fried, Michel Chonchol, Bryan Kestenbaum, Bruce M. Psaty, David S. Siscovick, Michael G. Shlipak   +9 more
openalex   +2 more sources

Comparative assessment of renal function by cystatin C level in patients with hypertension and extrasystole

, 2020
А. V. Іvankova, N. V. Kuzmіnova, S. E. Lozinsky, V. P. Іvanov   +3 more
openalex   +2 more sources

On the measurement of glomerular filtration rate: An odyssey into the milieu intérieur

Experimental Physiology, EarlyView.
Anders Møller Greve, Anna Agnes Lytzen, Hrefna Sæunn Einarsdóttir, Michael Perch, Ronan M. G. Berg   +4 more
wiley   +1 more source

Prediabetes Associates With Musculoskeletal Alterations Independent of Total Body Adiposity

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 1, February 2026.
ABSTRACT Background Excess adiposity is a major risk factor for insulin resistance, prediabetes, and Type 2 diabetes and increases the risk for sarcopenia and osteosarcopenia later in life. It has been proposed that altered metabolic function and musculoskeletal status in people with obesity are directly linked, presumably because they share common ...
Alan Fappi, Clifton J. Holmes, Chao Cao, Vasavi Shabrish, Aman P. Aher, Karen Shen, Paul K. Commean, Dwight A. Towler, Dominic N. Reeds, Gretchen A. Meyer, Bettina Mittendorfer   +10 more
wiley   +1 more source

Neuro‐Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo, Hui Liu, Yu‐Jing Song, Jian‐Hua Wang, Danfeng Liu, Zhi‐Wei Zheng, Jia‐Jun Li, Boya Li, An Song, Wei He, Lei‐Lei Yang, Shuo Wang   +11 more
wiley   +1 more source

Development and Validation of a Novel Scoring Model Integrating Clinical Risk Factors and Pharmacokinetic Parameters to Predict Vancomycin‐Induced Nephrotoxicity

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 2, February 2026.
ABSTRACT Background Vancomycin (VCM), a first‐line treatment option for infections caused by methicillin‐resistant Staphylococcus aureus, has been reported to cause nephrotoxicity even within therapeutic concentration ranges. Traditional therapeutic drug monitoring strategies rely primarily on the area under the concentration–time curve (AUC), without ...
Yoshihiko Matsuki, Ken‐ichi Sako, Yutaro Kozima, Tamaki Watanabe, Yasuharu Kashiwagura, Nobuhiro Yasuno, Shigekazu Watanabe   +6 more
wiley   +1 more source

Pharmacokinetics and Customized Dosing of Vancomycin in Adult Patients With Hematological Malignancies: Status, Challenges, and Opportunities

Pharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
Framework diagram of CDvan informed by MCS (Eucast, European committee for antimicrobial susceptibility testing; CLSI, clinical and laboratory standard institute). ABSTRACT Vancomycin (VAN) remains the first‐line treatment for methicillin‐resistant, multidrug‐resistant gram‐positive bacterial infections, even among cancer patients.
Xiangqing Song, Meizi Zeng, Tao Yang, Mi Han   +3 more
wiley   +1 more source

Cystatin C, Albuminuria, and 5-Year All-Cause Mortality in HIV-Infected Persons

, 2010
Andy I. Choi, Rebecca Scherzer, Peter Bacchetti, Phyllis C. Tien, Michael S. Saag, Cynthia L. Gibert, Lynda A. Szczech, Carl Grünfeld, Michael G. Shlipak   +8 more
openalex   +2 more sources

First‐in‐Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin‐S Inhibitor, in Healthy Adult Subjects

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT ASP1617 is a novel, highly selective inhibitor of cathepsin‐S, an important protease for antigen peptide loading onto major histocompatibility complex class II molecules. Preclinically, ASP1617 prevented progression of lupus‐like glomerulonephritis in an NZB/W F1 mouse model of systemic lupus erythematosus.
Tomoki Kojima, Wei Chen, Ronald Smulders, Stephen Stanhope, Donna Kowalski, Nakyo Heo, Selina Moy, Amanda Goldston, David Han, Tong Zhu   +9 more
wiley   +1 more source